Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Crab fishermen in Alaska have been scrambling to stay afloat after two years of the Bering Sea fishery being closed or severely curtailed due to plummeting crab numbers. And they're concerned that more of the same awaits this October when officials decide on catch limits for the upcoming season.
Most major car brands admit they may be selling your personal data — though they are vague on the buyers, and half say they would share it with the government or law enforcement without a court order.
Tourism-related businesses have always been at the mercy of the weather. But with heat waves, fires and storms becoming more frequent and intense, small businesses increasingly see extreme weather as their next long-term challenge.
